Bone Therapeutics announced topline data from a phase 3 study evaluating enhanced viscosupplement JTA-004 in patients with knee osteoarthritis. JTA-004 did not meet the primary…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.